Form 4: Vir Biotechnology Director Janet Napolitano Acquires Shares and Options

Director Janet Napolitano reports acquisition of Vir Biotechnology shares and stock options.

Summary

• On May 30, 2024, Janet Napolitano, a director of Vir Biotechnology, acquired 8,000 shares of common stock at $0.
• Following the transaction, Napolitano directly owns 23,806 shares of common stock.
• Napolitano also acquired stock options for 16,000 shares of common stock with an exercise price of $10.39, exercisable from May 30, 2025, to May 29, 2034.
• Following the transaction, Napolitano directly owns 16,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock and option acquisition. While insider buying can be seen as positive, this is a standard transaction.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing insights into the actions of company directors and officers.

Stakeholder Impact

• The acquisition of shares and options by a director could positively influence shareholder sentiment.

Key Dates